192 related articles for article (PubMed ID: 36909726)
1. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation.
Guo Y; Han J; Zhang Y; Jin C; Zhang Y; He J; Chen S; Guo Y; Lin Y; Li F; Yang F; Shen Z; Mao R; Zhu H; Zhang J
Front Cell Infect Microbiol; 2023; 13():1120300. PubMed ID: 36909726
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
3. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
[TBL] [Abstract][Full Text] [Related]
4. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
5. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
6. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
7. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
Luo H; Tan G; Hu X; Li Y; Lei D; Zeng Y; Qin B
Virol J; 2023 Jul; 20(1):161. PubMed ID: 37475028
[TBL] [Abstract][Full Text] [Related]
8. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
9. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.
Li M; Sun F; Bi X; Lin Y; Yang L; Lu Y; Zhang L; Wan G; Yi W; Zhao L; Xie Y
Virol Sin; 2022 Jun; 37(3):390-397. PubMed ID: 35257963
[TBL] [Abstract][Full Text] [Related]
10. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.
Li M; Zhang L; Xie S; Sun F; Zeng Z; Deng W; Jiang T; Bi X; Lin Y; Yang L; Lu Y; Shen G; Liu R; Wu S; Chang M; Hu L; Dong J; Yi W; Xie Y
Front Immunol; 2022; 13():892031. PubMed ID: 35603222
[TBL] [Abstract][Full Text] [Related]
12. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
13. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
14. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
Al Mahtab M; Akbar SMF; Aguilar JC; Guillen G; Penton E; Tuero A; Yoshida O; Hiasa Y; Onji M
PLoS One; 2018; 13(8):e0201236. PubMed ID: 30133478
[TBL] [Abstract][Full Text] [Related]
19. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
[TBL] [Abstract][Full Text] [Related]
20. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
